Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Latest, Q2 2026
14.2%
Period ended Jun 30, 2026
Change on a year earlier
+5.5 pts
8.7% in Q2 2025
History
35 quarters
Since Q1 2015
Sources
28
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | GAAP Effective Tax Rate (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 14.2% | +5.5 pts | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 12.7% | +0.4 pts | Form 10-Q (filed 2026-05-01) ↗ |
| Q3 2025 | Sep 30, 2025 | 18.0% | +9.3 pts | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 8.7% | +2.7 pts | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 12.3% | +78.5 pts | Form 10-Q (filed 2026-05-01) ↗ |
| Q3 2024 | Sep 30, 2024 | 8.7% | -2.4 pts | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2024 | Jun 30, 2024 | 6.0% | -8.6 pts | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2024 | Mar 31, 2024 | -66.2% | -83.7 pts | Form 10-Q (filed 2025-05-02) ↗ |
| Q3 2023 | Sep 30, 2023 | 11.1% | +0.7 pts | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2023 | Jun 30, 2023 | 14.6% | +0.6 pts | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 17.5% | +5.6 pts | Form 10-Q (filed 2024-05-03) ↗ |
| Q3 2022 | Sep 30, 2022 | 10.4% | -2.2 pts | Form 10-Q (filed 2023-10-31) ↗ |
| Q2 2022 | Jun 30, 2022 | 14.0% | -2.8 pts | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 11.9% | +0.5 pts | Form 10-Q (filed 2023-04-28) ↗ |
| Q3 2021 | Sep 30, 2021 | 12.6% | +4.2 pts | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 16.8% | +5.6 pts | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 11.4% | +1.7 pts | Form 10-Q (filed 2022-04-28) ↗ |
| Q3 2020 | Sep 30, 2020 | 8.4% | -5.2 pts | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | 11.2% | -3.8 pts | Form 10-Q (filed 2021-08-04) ↗ |
| Q1 2020 | Mar 31, 2020 | 9.7% | -4.2 pts | Form 10-Q (filed 2021-04-28) ↗ |
| Q3 2019 | Sep 30, 2019 | 13.6% | +2.4 pts | Form 10-Q (filed 2020-10-29) ↗ |
| Q2 2019 | Jun 30, 2019 | 15.0% | +1.7 pts | Form 10-Q (filed 2020-07-29) ↗ |
| Q1 2019 | Mar 31, 2019 | 13.9% | +2.1 pts | Form 10-Q (filed 2020-05-01) ↗ |
| Q3 2018 | Sep 30, 2018 | 11.2% | -3.9 pts | Form 10-Q (filed 2019-10-30) ↗ |
| Q2 2018 | Jun 30, 2018 | 13.3% | -2.1 pts | Form 10-Q (filed 2019-07-31) ↗ |
| Q1 2018 | Mar 31, 2018 | 11.8% | -4.0 pts | Form 10-Q (filed 2019-05-01) ↗ |
| Q3 2017 | Sep 30, 2017 | 15.1% | -1.5 pts | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2017 | Jun 30, 2017 | 15.4% | +0.2 pts | Form 10-Q (filed 2018-07-27) ↗ |
| Q1 2017 | Mar 31, 2017 | 15.8% | -0.1 pts | Form 10-Q (filed 2018-04-25) ↗ |
| Q3 2016 | Sep 30, 2016 | 16.6% | +1.6 pts | 10-Q FY2016 (XBRL) ↗ |
| Q2 2016 | Jun 30, 2016 | 15.2% | -2.0 pts | 10-Q FY2016 (XBRL) ↗ |
| Q1 2016 | Mar 31, 2016 | 15.9% | +2.4 pts | 10-Q FY2016 (XBRL) ↗ |
| Q3 2015 | Sep 30, 2015 | 15.0% | – | 10-Q FY2015 (XBRL) ↗ |
| Q2 2015 | Jun 30, 2015 | 17.2% | – | 10-Q FY2015 (XBRL) ↗ |
| Q1 2015 | Mar 31, 2015 | 13.5% | – | 10-Q FY2015 (XBRL) ↗ |
Breakdown
What makes up gaap effective tax rate (%)
- U.S. Federal Statutory Income Tax Rate (%)–
- Effective Tax Rate Reconciliation — Foreign Rate Differential (including Puerto Rico) (legacy) (%)–
- Effective Tax Rate Reconciliation — Foreign-Derived Intangible Income (FDII) Deduction (%)–
- Effective Tax Rate Reconciliation — Federal R&D Tax Credits (%)–
- Effective Tax Rate Reconciliation — Interest on Unrecognized Tax Benefits (legacy) (%)–
Cite this data
StockData. (2026). Amgen GAAP Effective Tax Rate (%) (%), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/etr_tot
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.